Global Health Limited

rs,

Ref:- GHL/2023-24/EXCH/77 The General Manager Dept. of Corporate Services BSE Limited, P J Towers, Dalal Street, Mumbai - 400 001 The Manager Listing Department National Stock Exchange of India

INR 8,647 million

obust performance during the quarter driven by growth in patient volumes e m o c n I l a t o T INR 8,647 million Q2 FY23 6,946 million 24.5% d n a A D T I B E i % s n g r a M INR 2,336 million Margin: 27.0%

6,946 million

e quarter driven by growth in patient volumes e m o c n I l a t o T INR 8,647 million Q2 FY23 6,946 million 24.5% d n a A D T I B E i % s n g r a M INR 2,336 million Margin: 27.0% Q2 FY23 1,721 million

24.5%

en by growth in patient volumes e m o c n I l a t o T INR 8,647 million Q2 FY23 6,946 million 24.5% d n a A D T I B E i % s n g r a M INR 2,336 million Margin: 27.0% Q2 FY23 1,721 million Margin

INR 2,336 million

I l a t o T INR 8,647 million Q2 FY23 6,946 million 24.5% d n a A D T I B E i % s n g r a M INR 2,336 million Margin: 27.0% Q2 FY23 1,721 million Margin: 24.8% 35.7% d n a T A P i % s n g r a M INR 1,252

27.0%

illion Q2 FY23 6,946 million 24.5% d n a A D T I B E i % s n g r a M INR 2,336 million Margin: 27.0% Q2 FY23 1,721 million Margin: 24.8% 35.7% d n a T A P i % s n g r a M INR 1,252 million Margin

1,721 million

6,946 million 24.5% d n a A D T I B E i % s n g r a M INR 2,336 million Margin: 27.0% Q2 FY23 1,721 million Margin: 24.8% 35.7% d n a T A P i % s n g r a M INR 1,252 million Margin: 14.5% Q2 FY23 857 mn

24.8%

d n a A D T I B E i % s n g r a M INR 2,336 million Margin: 27.0% Q2 FY23 1,721 million Margin: 24.8% 35.7% d n a T A P i % s n g r a M INR 1,252 million Margin: 14.5% Q2 FY23 857 mn Margin: 12.3%

35.7%

A D T I B E i % s n g r a M INR 2,336 million Margin: 27.0% Q2 FY23 1,721 million Margin: 24.8% 35.7% d n a T A P i % s n g r a M INR 1,252 million Margin: 14.5% Q2 FY23 857 mn Margin: 12.3% 46.1%

INR 1,252 million

36 million Margin: 27.0% Q2 FY23 1,721 million Margin: 24.8% 35.7% d n a T A P i % s n g r a M INR 1,252 million Margin: 14.5% Q2 FY23 857 mn Margin: 12.3% 46.1% d e B d e p u c c O i s y a D 132,565 ) R N

14.5%

Q2 FY23 1,721 million Margin: 24.8% 35.7% d n a T A P i % s n g r a M INR 1,252 million Margin: 14.5% Q2 FY23 857 mn Margin: 12.3% 46.1% d e B d e p u c c O i s y a D 132,565 ) R N I ( 61,003

12.3%

24.8% 35.7% d n a T A P i % s n g r a M INR 1,252 million Margin: 14.5% Q2 FY23 857 mn Margin: 12.3% 46.1% d e B d e p u c c O i s y a D 132,565 ) R N I ( 61,003 Q2 FY23 112,503 17.8% * B O

“~60% of the planned bed addition will be at existing hospitals; resulting in lower capex / bed • Floor area of 100K+ sq.”

Sub

1

Notes

1

Sub

Investor Presentation Dear Sir(s), Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copy of Investor Presentation for the Second Quarter and Half Year ended September 30, 2023 Results of the Company. Kindly take the above on record. Thanking you, Yours faithfully For Global Health Limited Rahul Ranjan Company Secretary & Compliance Officer M. No. A17035 Encl: a/a Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411 www.medanta.org, info@medanta.org, CIN: L85110DL2004PLC128319 GLOBAL HEALTH LIMITED Dedicated to Life INVESTOR PRESENTATION Q2 FY2024 5 1 Contents 01 02 Q2 FY2024 Performance Update Medanta: Poised to Deliver Sustainable Growth 03 About Us 2 01 Q2 FY2024 Performance Update 3 Q2 FY2024 performance summary Robust performance during the quarter driven by growth in patient volumes e m o c n I l a t o T INR 8,647 million Q2 FY23 6,946 million 24.5% d

Notes

1. Revenue from healthcare services excludes pharmacy revenue and other income 2. Revenue breakdowns are provided as per internal MIS at the Company’s consolidated level 3. Cancer includes medical oncology, radiation oncology, head & neck surgery, bone marrow transplant and breast surgery 14 Growth seen in both mature and new hospitals Volume led growth seen across all units Matured hospitals - Over 6 years Developing hospitals - Less than 6 years Total Income (INR million) EBITDA (INR million and margin %) Total Income (INR million) EBITDA (INR million and margin %) +19.5% 6,064 5,073 +32.8% 1,545 1,163 +40.3% 2,643 1,884 +60.5% 897 559 Q2 FY23 Q2 FY24 Q2 FY23 Q2 FY24 Q2 FY23 Q2 FY24 Q2 FY23 Q2 FY24 22.9% 25.5% 29.7% 33.9% Occupied Bed Days ARPOB* (INR) Occupied Bed Days ARPOB* (INR) +9.7% 80,986 88,847 +7.2% 58,896 63,132 +38.7% +0.5% 43,718 56,823 57,082 31,517 Q2 FY23 Q2 FY24 Q2 FY23 Q2 FY24 Q2 FY23 Q2 FY24 Q2 FY23 Q2 FY24 60% 65% 57% 64% *ARPOB is calculated on Hospital Revenues e